OTC Mevacor Prospects Bleak In Light Of Short Post-Panel Review Period
This article was originally published in The Tan Sheet
Executive Summary
The timing of Merck's PDUFA deadline in relation to the recent advisory panel review of Mevacor Daily suggests FDA is unlikely to deem the OTC switch application "approvable.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning